Coagulation Parameters in Human Immunodeficiency Virus Infected Patients: A Systematic Review and Meta-Analysis

Table 1

Characteristics of the included studies on the coagulation profile of HIV-infected patients.

Author names, publication year	Country	Study design	Sample size			Age groups	Quality score
			HAART	HAART naïve	Seronegative controls
Leticia et al., 2014 [35]	Nigeria	Case-control	114	—	50	Adult	9
Ephraim et al., 2018 [43]	Ghana	Case-control	65	45	—	All age	8
Raman et al., 2016 [39]	India	Case-control	76	44	40	NR	8
Abdollahi et al., 2013 [44]	Iran	Case-control	114	—	114	Adult	8
Ifeanyichukwu et al., 2016 [34]	Nigeria	Case-control	61	61	60	Adult	9
Osime et al., 2015 [38]	Nigeria	Comparative	50	50	—	NR	7
Ifeanyi and Obeagu, 2015 [33]	Nigeria	Case-control	114	—	50	Adult	6
de Magalhães et al., 2020 [45]	Brazil	Cross-sectional	115	—	88	Elder	9
Omoregie et al., 2009 [37]	Nigeria	Case control	-	70	30	NR	7
Youmash et al., 2018 [40]	India	Cross-sectional	50	50	—	NR	8
Nasir et al., 2016 [36]	Nigeria	Cross-sectional	128	63	—	Adult	9
Chekwube Eluke et al., 2017 [32]	Nigeria	Cross-sectional	30	30	30	NR	7
Aisabokhale et al., 2019 [30]	Nigeria	Comparative	84	12	56	Adult	8
Fink et al., 2021 [47]	Denmark	Case control	936	—	2955	Adult	9
Amilo et al., 2014 [31]	Nigeria	Case-control	60	60	61	Adult	8
Himmat and Gaufri [41]	Sudan	Case-control	50	—	50	NR	8
Jong et al. [46]	Netherland	Comparative	112	48	—	Adult	8
Teasdale et al. [42]	Kenya	Prospective cohort	611	611	—	Adult	9

HAART, highly active antiretroviral therapy; NR, not reported.